Table I.
Demographic and Baseline Clinical Characteristics for Patients in the Study Sample
| Characteristic | Control group (n = 145) | Treatment group (n = 144) |
|---|---|---|
| Age (M ± SD) | 14.5 ± 1.7 | 14.6 ± 1.8 |
| Sex (n, %) | ||
| Male | 34 (23%) | 46 (32%) |
| Female | 111 (77%) | 98 (68%) |
| Race (n, %) | ||
| White | 126 (87%) | 122 (85%) |
| American Indian or Alaskan Native | 1 (1%) | 3 (2%) |
| Asian | 5 (3%) | 2 (1%) |
| Black or African American | 3 (2%) | 7 (5%) |
| Native Hawaiian or Other Pacific Islander | 0 (0%) | 0 (0%) |
| Mixed | 10 (7%) | 10 (7%) |
| Ethnicity (n, %) | ||
| Not Hispanic or Latino | 128 (88%) | 122 (85%) |
| Hispanic or Latino | 17 (12%) | 22 (15%) |
| Disease Subtype (n, %) | ||
| Oligoarticular (extended or persistent) | 29 (20%) | 31 (22%) |
| Polyarticular (RF−, RF+, or RF unknown) | 62 (43%) | 68 (47%) |
| Other (enthesitis-related JIA, psoriatic, systemic, and undifferentiated) | 54 (37%) | 45 (31%) |
| Medications (%) | ||
| NSAID | 55 (38%) | 49 (34%) |
| Non-biologic DMARD | 81 (56%) | 66 (46%) |
| Biologic response modifier | 67 (46%) | 66 (46%) |
| Corticosteroid | 10 (7%) | 6 (4%) |
| Physician-rated disease severity (n, %) | ||
| Mild | 118 (81%) | 118 (82%) |
| Moderate or severe | 27 (19%) | 26 (18%) |
Note. There were no significant group differences on any of the baseline demographic and clinical characteristics shown in this table. NSAID = non-steroidal anti-inflammatory drug; DMARD = disease-modifying anti-rheumatic drug.